Veracyte buys Convergent Genomics to add urine-based bladder cancer test
What's the deal? Veracyte has acquired Convergent GenomicsDealroom has a profile for this one. Try Dealroom →, adding its UroAmp platform and proprietary urinary tumor DNA (utDNA) technology to the cancer diagnostics company's portfolio. Terms were not disclosed. UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.
What's the endgame? Veracyte plans to combine UroAmp with its existing Decipher Bladder and TrueMRD tests to deliver insights from urine, tissue, and blood across bladder cancer care.
Why urine? NMIBC is generally confined to the bladder and may shed only limited tumor DNA into the bloodstream, making blood-based detection difficult. Urine, by contrast, comes into direct contact with the tumor and offers a richer source of genomic information.
Why now? In the US, roughly 85,000 patients are diagnosed with bladder cancer annually, including about 65,000 with NMIBC. Of the 750,000 people living with the disease, some 600,000 have NMIBC.
"Bladder cancer care is advancing quickly, yet clinicians and patients still face significant uncertainty at critical decision points," said Marc Stapley, Veracyte's chief executive officer. He said UroAmp is "especially well suited to non-muscle-invasive disease."
What's the evidence? UroAmp is backed by nine peer-reviewed publications and more than 40 posters and abstracts. In the RUMBLE study, patients who tested clinically negative after induction Bacillus Calmette-Guerin therapy but positive for utDNA had a 12-month recurrence-free survival rate of 25%, compared with 91% among utDNA-negative patients.
What's next? Veracyte's first test will help determine whether patients who completed BCG induction therapy are likely to benefit from maintenance treatment. It expects to commercialise the test in late 2028, subject to reimbursement timelines, and plans to expand UroAmp to additional indications.
The signal: The deal reflects a push in cancer diagnostics toward layering complementary tests — across urine, tissue, and blood — to guide treatment at each stage of a patient's care.
Read more: finance.yahoo.com
Image credit: Centers for Disease Control and Prevention
